MDXG vs PROK
MDXG: MiMedx is a regenerative medicine company specializing in placental tissue-based therapies for advanced wound care and surgical applications. PROK: ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation.
Side-by-side fundamentals
| Metric | MDXG | PROK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $4.26 | $1.54 | |
| Market cap as of 2026-08-03 | $621M | $465M | |
| P/E as of 2026-08-03 | 19.61 | n/a | |
| Net margin as of 2026-08-03 | +7.9% | -8131.5% | MDXG higher |
| Gross margin as of 2026-08-03 | +81.0% | n/a | |
| Operating margin as of 2026-08-03 | +10.2% | -18959.7% | MDXG higher |
| ROE as of 2026-08-03 | +12.9% | -28.1% | MDXG higher |
| ROA as of 2026-08-03 | +9.7% | -21.4% | MDXG higher |
| Debt / equity as of 2026-08-03 | 0.07 | 5.40 | MDXG lower |
| Revenue growth (YoY) as of 2026-08-03 | +10.5% | +190.5% | PROK higher |
| Revenue CAGR (3y) SEC XBRL | +16.1% | n/a | |
| Beta as of 2026-08-03 | 1.47 | 1.81 | |
| 1-year return as of 2026-07-27 close | -37.1% | -53.2% | MDXG higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.